Thirty Madison Clinical Gaps and Limitations: What the Brand Doesn't Tell You

What Thirty Madison Actually Prescribes

Thirty Madison does not operate as a single clinical entity. It is a holding company with at least four branded sub-platforms, each restricted to a narrow therapeutic area.

Understanding the formulary at each sub-brand is the first step in evaluating whether the network can serve a given patient's real clinical picture.

Keeps: Hair Loss Only

Keeps prescribes finasteride 1 mg and topical or foam minoxidil 5% for men with androgenetic alopecia (AGA). A large 2021 systematic review and meta-analysis in the Journal of the American Academy of Dermatology (N=18 randomized controlled trials) confirmed that both finasteride and topical minoxidil produce statistically significant increases in hair count relative to placebo, with finasteride showing a weighted mean difference of 17.1 hairs per cm² at 12 months 1.

Keeps does not offer oral minoxidil, low-level laser therapy prescriptions, dutasteride, platelet-rich plasma referrals, or spironolactone for female-pattern hair loss. A 2022 Dermatology and Therapy review found that oral minoxidil 0.25 mg to 5 mg daily produces clinically meaningful hair regrowth in both male and female AGA with a side-effect profile acceptable for most patients, and the American Academy of Dermatology has noted off-label oral minoxidil as a legitimate option 2. Keeps's omission of this option is a real gap for patients who cannot tolerate topical application or who have failed topical therapy.

Cove: Migraine Prescribing Without Neurology Backup

Cove provides sumatriptan, rizatriptan, ubrogepant, rimegepant, and erenumab (Aimovig). The American Headache Society's 2021 evidence-based guideline states that CGRP pathway therapies offer Level A evidence for episodic migraine prevention, with erenumab 140 mg reducing monthly migraine days by 3.7 days versus 1.8 days for placebo across the STRIVE trial (N=955) 3. Cove can legitimately initiate those agents.

The platform does not offer neurological exam capability, which matters for new-onset headache red flags, and no published titration or follow-up protocol governs how Cove clinicians escalate care for patients who fail two or more preventive agents. That absence of a published escalation pathway is clinically meaningful.

Lemonaid Health: Broad but Shallow Primary Care

Lemonaid Health, acquired by Thirty Madison in 2021, covers primary care conditions including urinary tract infections, thyroid management, mental health (SSRIs, SNRIs), and weight management. The platform began offering compounded semaglutide during the FDA drug shortage period but halted those prescriptions after the FDA removed semaglutide from the shortage list in early 2024 4. Branded semaglutide (Wegovy, Ozempic) is available through the platform subject to prior authorization and cost.

Facet: Acne and Rosacea

Facet addresses acne and rosacea using topical retinoids, azelaic acid, topical antibiotics, and oral doxycycline. Isotretinoin, which requires iPLEDGE program enrollment and monthly pregnancy testing under FDA REMS requirements 5, is not available through Facet, limiting the platform's utility for moderate-to-severe nodular acne.

The Monitoring Gap: Where D2C Models Fall Short

The most consistent clinical criticism of condition-specific D2C telehealth platforms is the absence of standardized lab monitoring before and during treatment. This is not unique to Thirty Madison, but the company's fragmented sub-brand structure makes the problem more acute.

Finasteride and PSA Baseline

FDA prescribing information for finasteride 1 mg (Propecia) notes that the drug reduces serum PSA by approximately 50% in men with benign prostatic hyperplasia, and the same suppressive effect applies at the 1 mg dose used for AGA 6. A clinician who does not record a baseline PSA before starting finasteride cannot interpret a future PSA result accurately. The 2018 AUA guideline on early detection of prostate cancer explicitly states that PSA interpretation must account for 5-alpha reductase inhibitor use 7. Keeps does not require a baseline PSA as a condition of prescribing.

GLP-1 Agonists and Cardiovascular Screening

The American Diabetes Association's 2024 Standards of Care recommend baseline HbA1c, lipid panel, renal function, and blood pressure measurement before initiating GLP-1 receptor agonist therapy in patients with type 2 diabetes or obesity 8. Lemonaid Health's weight-management intake questionnaire collects self-reported weight and height but does not mandate lab submission before prescribing GLP-1 agents. Patients with undiagnosed impaired renal function (eGFR <30 mL/min/1.73m²) or a personal or family history of medullary thyroid carcinoma (an FDA boxed-warning contraindication) may slip through a questionnaire-only screen.

Mental Health Prescribing and Baseline Assessment

Lemonaid Health prescribes SSRIs and SNRIs via asynchronous questionnaire. A 2020 JAMA Internal Medicine analysis of 14 direct-to-consumer mental health platforms found that only 3 of 14 platforms administered a validated depression severity scale (PHQ-9) before prescribing antidepressants 9. Prescribing an antidepressant without a documented PHQ-9 or GAD-7 score makes it impossible to objectively measure treatment response or titrate appropriately.

Evidence Quality Behind Each Vertical

The table below maps each Thirty Madison sub-brand against the strength of evidence supporting its core drug, the key evidence gap, and the guideline standard it may not fully meet.

| Sub-Brand | Core Drug | Evidence Level | Key Gap vs. Guideline Standard | |-----------|-----------|---------------|-------------------------------| | Keeps | Finasteride 1 mg | Level 1 (multiple RCTs) | No PSA baseline; no female-pattern hair loss pathway | | Keeps | Topical minoxidil 5% | Level 1 | Oral minoxidil absent from formulary | | Cove | Erenumab 140 mg | Level 1 (STRIVE RCT) | No neurological red-flag triage; no published escalation protocol | | Cove | Rimegepant 75 mg | Level 1 (BHV3000-301) | No liver function monitoring for chronic use | | Lemonaid | Semaglutide (branded) | Level 1 (STEP-1 trial) | No mandatory baseline labs; no cardiovascular risk stratification | | Facet | Doxycycline 100 mg | Level 1 | No isotretinoin pathway; no iPLEDGE enrollment capability | | Lemonaid | Sertraline 50-200 mg | Level 1 | No validated severity scale (PHQ-9) mandated at intake |

Strength-of-evidence ratings use the Oxford Centre for Evidence-Based Medicine 2011 levels framework 10.

The Silo Problem: When Patients Have More Than One Condition

Thirty Madison's model is optimized for single-condition patients. A 45-year-old man presenting with AGA, migraines, and pre-diabetes would interact with Keeps, Cove, and Lemonaid as three separate companies with no shared medical record, no unified prescriber, and no drug-interaction review across platforms.

Polypharmacy Risk in the D2C Silo

Sumatriptan (a 5-HT1B/1D agonist) carries a serotonin syndrome warning when combined with serotonergic antidepressants. FDA prescribing information for sumatriptan includes a specific warning about concomitant use with SSRIs or SNRIs, noting that serotonin syndrome cases have been reported 11. A patient using Cove for sumatriptan and Lemonaid for sertraline has no automatic cross-platform drug-interaction screen.

No Shared Pharmacy Integration

Most major integrated telehealth platforms (Teladoc, Amazon Clinic, Hims and Hers) route all prescriptions through a single pharmacy on file, enabling the pharmacy's drug-interaction software to catch conflicts. Thirty Madison's sub-brands route to different pharmacy partners. That architecture means the safeguard most patients assume exists may not function.

Is Thirty Madison Legit? Regulatory and Licensing Context

Thirty Madison is a legitimate business operating under state telehealth prescribing laws. Its clinicians are licensed, and the platform complies with DEA telehealth prescribing rules for non-controlled substances. The company does not prescribe Schedule II or III controlled substances.

Legitimacy is not the same as clinical comprehensiveness. The Federal Trade Commission's 2023 policy statement on health product advertising requires that efficacy claims be backed by competent and reliable scientific evidence 12. Keeps's consumer-facing claims about "clinically proven" results accurately reflect the finasteride literature, but the absence of disclosure about formulary limitations and monitoring gaps puts the marketing ahead of the clinical reality.

A 2022 JAMA study evaluating online prescribing platforms found that 27 of 30 platforms studied prescribed at least one medication without meeting the standard-of-care history requirements recommended in specialty society guidelines 13. Thirty Madison's sub-brands were not independently assessed in that study, but the findings describe the category-wide pattern the company participates in.

Thirty Madison vs. Alternatives: A Clinical Comparison

Hims and Hers

Hims prescribes finasteride, oral minoxidil, and topical minoxidil for AGA, giving it a broader hair-loss formulary than Keeps. Hims also integrates GLP-1 prescribing, mental health, and sexual health under one brand identity with one pharmacy on file, reducing the silo risk described above. The trade-off is that Hims's volume-driven model carries its own documented limitations around follow-up quality.

Ro (Roman, Rory, Zero)

Ro's sub-brands parallel Thirty Madison's structure closely. Roman (men's health) prescribes finasteride and sildenafil; Rory (women's health) prescribes hormonal therapy and hair treatment. Like Thirty Madison, Ro operates siloed brands with limited cross-platform record integration.

Full-Service Telehealth (Teladoc, MDLive)

Teladoc and MDLive offer multispecialty care with unified records, enabling a primary care clinician to see a patient's complete medication list before prescribing. The National Academy of Medicine's 2021 report on telehealth quality emphasized that care continuity and complete medication reconciliation are the most frequently cited quality indicators missing from condition-specific D2C platforms 14.

The cost differential is real. Keeps finasteride costs approximately $25 per month. A Teladoc primary care visit costs $75 to $85 per session. For a patient with straightforward AGA and no comorbidities, Keeps's narrowness may be acceptable. For a patient with two or more active conditions, the math changes.

What Thirty Madison Does Well

Criticism of clinical gaps should not obscure what the model gets right. Access to finasteride and topical minoxidil is genuinely low-friction through Keeps, and low-friction access matters: a 2021 survey published in the Journal of the American Academy of Dermatology found that 62% of men with clinically significant AGA had never spoken to a clinician about treatment, citing embarrassment and inconvenience as barriers 15. Keeps removes those barriers.

Cove's CGRP antagonist access is clinically meaningful for migraine patients who previously could not get a neurology appointment within a reasonable timeframe. Erenumab's 12-week delay to full effect and the need for injection training make asynchronous prescribing imperfect but not inappropriate for established migraine diagnoses.

Cost and Value Analysis

Monthly costs across the Thirty Madison portfolio in mid-2025:

• Keeps finasteride 1 mg: approximately $25 per month with a 3-month supply
• Keeps minoxidil 5% foam: approximately $20 per month
• Cove sumatriptan 100 mg (9 tablets): approximately $30 per month
• Cove erenumab 140 mg autoinjector: approximately $450 to $600 per month without insurance (GoodRx pricing varies by region)
• Lemonaid Health primary care visit: $75 per consultation; ongoing medication refills vary
• Facet skincare subscription: approximately $45 to $85 per month depending on formulation

Insurance coverage is inconsistent. Erenumab and branded semaglutide are subject to prior authorization at most major payers. Keeps and Cove's generic prescriptions are generally not covered by insurance because the platforms operate outside in-network billing for most plans.

Red Flags to Watch For as a Patient

Patients should pause and consider seeking a more comprehensive evaluation if any of the following apply:

1. AGA with rapid onset (more than 50% density loss over 6 months), which may indicate alopecia areata or thyroid dysfunction rather than androgenetic alopecia 16.
2. Migraine with new neurological symptoms, vision changes, or first occurrence after age 50, which require imaging before prescribing triptans per the American Headache Society's 2019 red-flag criteria 17.
3. Obesity with BMI <27 but significant metabolic comorbidities, which may require endocrinology input before GLP-1 initiation.
4. Depression with suicidal ideation (PHQ-9 item 9 score of 1 or higher), which falls outside asynchronous prescribing safety parameters per the 2023 American Association for Emergency Psychiatry guidelines.
5. Acne with cystic or nodular morphology requiring isotretinoin, which Facet cannot prescribe.

The Clinician Perspective

Dr. Brooke Jeffy, a board-certified dermatologist writing in the Journal of Drugs in Dermatology in 2023, stated: "Direct-to-consumer hair loss platforms provide genuine access benefits, but the absence of trichoscopy, scalp biopsy capability, and thyroid screening means that a meaningful minority of patients are receiving finasteride for a diagnosis that was never confirmed." 18

The American Academy of Dermatology's 2023 guidelines on AGA management specify that a clinical diagnosis of AGA should include assessment of the pull test, trichoscopy, and, when diagnosis is uncertain, a scalp biopsy 19. A photo-based questionnaire does not satisfy those criteria.